The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor in myoma and adenomyosis
| Autor: | Jae Yen Song, Jang Heub Kim, Youn Jee Chung, Shin Young Kim, Mee Ran Kim, Minkyoung Lee, Hye Min Moon, Hyun Hee Cho |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
myoma
Endometrium lcsh:Gynecology and obstetrics Andrology 03 medical and health sciences 0302 clinical medicine Anti-Müllerian hormone receptor anti-müllerian hormone Medicine Adenomyosis lcsh:RG1-991 030219 obstetrics & reproductive medicine Uterine leiomyoma biology business.industry Myometrium Obstetrics and Gynecology Myoma Anti-Müllerian hormone medicine.disease medicine.anatomical_structure Leiomyoma adenomyosis 030220 oncology & carcinogenesis biology.protein Original Article General Gynecology business anti-müllerian hormone receptor |
| Zdroj: | Obstetrics & Gynecology Science, Vol 61, Iss 1, Pp 127-134 (2018) Obstetrics & Gynecology Science |
| ISSN: | 2287-8580 2287-8572 |
| Popis: | Objective We compared the expression levels of Mullerian inhibiting substance (MIS)/anti-Mullerian hormone type II receptor (AMHRII) in uterine myoma and adenomyosis to evaluate the possibility of using MIS/anti-Mullerian hormone (AMH) as a biological regulator or therapeutic agent in patients with uterine leiomyoma and adenomyosis. Methods We studied normal uterine myometrium, leiomyoma, endometrial tissue, and adenomyosis from 57 patients who underwent hysterectomy for uterine leiomyoma (22 cases) or adenomyosis (28 cases) and myomectomy for uterine myoma (7 cases). Immunohistochemical staining was used to confirm the MIS/AMHRII protein expression level in each tissue. Reverse transcription-polymerase chain reaction was performed to quantify MIS/AMHRII mRNA expression. Results The MIS/AMHRII protein was more strongly expressed in uterine myoma (frequency of MIS/AMHRII expressing cells: 51.95%±13.96%) and adenomyosis (64.65%±4.85%) tissues than that in the normal uterine myometrium (3.15%±1.69%) and endometrium (31.10%±7.19%). In the quantitative analysis of MIS/AMHRII mRNA expression, MIS/AMHRII mRNA expression levels in uterine myoma (mean density: 4.51±0.26) and adenomyosis (6.84±0.20) tissues were higher than that in normal uterine myometrial tissue (0.08±0.09) and endometrial tissue (1.63±0.06). Conclusion This study demonstrated that MIS/AMHRII was highly and strongly expressed on uterine myoma and adenomyosis. Our data suggest that MIS/AMH may be evaluated as a biological modulator or therapeutic agent on MIS/AMHRII expressing uterine myoma and adenomyosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|